HIGHLIGHTS
- who: Torleif Tollefsrud Gju00f8lberg from the Oslo University , Oslo, Norway, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, , Penzberg, Germany. have published the article: Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life, in the Journal: (JOURNAL) of 11/05/2022
- what: The authors show that these effects do not relate directly to their FcRn-binding capacity at acidic pH in the absence of their Ag but rather to the biophysical differences of both ABTs and Ags which affect the ability of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.